NCT06354660

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 537 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

Conditions

• Diabetes Type 2

Interventions

Type	Name	Description
DRUG	Retatrutide	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2024-04-10
• Primary completion: 2026-01-22
• Completion: 2026-02-20
• First posted: 2024-04-09
• Last updated: 2026-03-05

Locations

48 sites across 4 countries: United States, India, Mexico, Puerto Rico

Regulatory

• FDA-regulated drug study